Astellas Pharma (4503.T)

Executive Summary

Astellas Pharma is a global pharmaceutical company headquartered in Tokyo, Japan, with a strong focus on oncology, urology, nephrology, and immunology. The company has established a portfolio of blockbuster drugs including Xtandi (enzalutamide) for prostate cancer and Padcev (enfortumab vedotin) for urothelial carcinoma, which have driven significant revenue growth. In fiscal year 2025, Astellas reported robust performance, with Xtandi and Padcev contributing to double-digit sales increases. The company's R&D pipeline is extensive, with over 1,100 projects across discovery through late-stage development, emphasizing next-generation therapies in oncology and specialty indications. Key upcoming milestones include regulatory decisions and pivotal data readouts. Astellas' late-stage pipeline features TAS-117 (an AKT inhibitor) in solid tumors, grapiprant (EP4 antagonist) in cancer immunotherapy, and continued expansion of Padcev into earlier lines of therapy. The company is also advancing its gene therapy and cell therapy platforms. With a disciplined capital allocation strategy and a focus on high-value orphan oncology indications, Astellas is positioned for sustained growth. However, patent expiries on legacy products like Vesicare (solifenacin) pose competitive pressures. Overall, Astellas' strong commercial execution and promising pipeline justify a positive outlook.

Upcoming Catalysts (preview)

• Q3 2026Padcev (enfortumab vedotin) FDA decision for first-line cisplatin-eligible urothelial carcinoma85% success
• Q4 2026TAS-117 (AKT inhibitor) Phase 2 data in HR+/HER2- breast cancer with AKT alterations60% success
• Q1 2027Grapiprant (EP4 antagonist) Phase 3 topline results in combination with checkpoint inhibitor for advanced solid tumors55% success